Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER

被引：2
|
作者：
Arnold, Suzanne V.
Tang, Fengming
Cooper, Andrew
Chen, Hungta
Gomes, Marilia B.
Rathmann, Wolfgang
Shimomura, Iichiro
Vora, Jiten
Watada, Hirotaka
Khunti, Kamlesh
Kosiborod, Mikhail N.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-324-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
324-OR
引用
收藏
页数：5
相关论文
共 50 条
  • [21] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    LANCET, 2021, 398 (10296): : 262 - 276
  • [22] GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
    Banerjee, Mainak
    Pal, Rimesh
    Maisnam, Indira
    Mukhopadhyay, Satinath
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (01)
  • [23] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [24] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [25] Optimising use of SGLT2 inhibitors and GLP1 receptor agonists across patients with type 2 diabetes
    Evans, M.
    McEwan, P.
    Foos, V.
    Jenkins, R.
    Roberts, G.
    Jones, M.
    Chen, J.
    DIABETOLOGIA, 2024, 67 : S352 - S353
  • [26] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [27] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [28] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [29] GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
    Patel, Rushin
    Wadid, Mark
    Makwana, Bhargav
    Kumar, Ashish
    Khadke, Sumanth
    Bhatti, Ammar
    Banker, Ahan
    Husami, Zaid
    Labib, Sherif
    Venesy, David
    Fonarow, Gregg
    Kosiborod, Mikhail
    Al-Kindi, Sadeer
    Bhatt, Deepak L.
    Dani, Sourbha
    Nohria, Anju
    Butler, Javed
    Ganatra, Sarju
    JACC-HEART FAILURE, 2024, 12 (11) : 1814 - 1826
  • [30] GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
    Neves, Joao Sergio
    Borges-Canha, Marta
    Vasques-Novoa, Francisco
    Green, Jennifer B.
    Leiter, Lawrence A.
    Granger, Christopher B.
    Carvalho, Davide
    Leite-Moreira, Adelino
    Hernandez, Adrian F.
    Del Prato, Stefano
    McMurray, John J. V.
    Md, Joao Pedro Ferreira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 517 - 525
12345